Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Inclusion Criteria:

   1. Males and females aged ≥18 years;

   2. ECOG performance status (PS) 0-2;

   3. Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not
   eligible);

   4. Received at least one prior systemic therapy, which may include stem cell transplant,
   for AL amyloidosis;

   5. Have adequate organ function;

   6. Ability to understand and willingness to sign informed consent prior to initiation of
   any study procedures.

Exclusion Criteria:

   1. Secondary or familial amyloidosis;

   2. Life expectancy of < 3 months;

   3. Symptomatic multiple myeloma;

   4. Hypersensitivities to other monoclonal antibodies;

   5. Known HIV infection;

   6. Women who are lactating;

   7. Any other condition or prior therapy, which in the opinion of the PI, would make the
   subject unsuitable for the study.